Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

NCT04575194 · Unknown status

Last updated 2026-05-28

This clinical trial tests how medications for obesity affect blood pressure in adults with obesity.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2020-09 · est. completion 2023-05

Where 1 site · Greece

What this study is testing ClinicalTrials.gov NCT04575194 ↗

Description as written by the study sponsor.

The aim of the present study is to compare the efficacy of liraglutide vs. naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after a test meal. The study will include 40 patients, who will further be divided into two treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). The patients will be examined at baseline, 3 and 6 months after the treatment initiation.

Treatments tested

Liraglutide 6 MG/ML [Saxenda] Drug

3 mg of sc liraglutide daily plus lifestyle intervention
Naltrexone-Bupropion Combination Drug

32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention

Main thing measured	Changes in blood pressure
Sponsor	National and Kapodistrian University of Athens
Conditions studied	Obesity, Blood Pressure
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04575194 ↗